Overview
Dr. Susan Scott is a thoracic medical oncologist with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital and Assistant Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Scott has expertise in thoracic malignancies, including non-small cell lung cancer, small cell lung cancer and pulmonary carcinoid tumors, as well as thymic malignancies. She leads the EGFR and HER2 lung cancer research program for Johns Hopkins. Dr. Scott received her undergraduate education at the University of Oxford, UK and medical doctorate from Yale University. She completed residency at the Cleveland Clinic where she also served as Chief Resident in Internal Medicine. Dr. Scott joined Johns Hopkins Oncology for fellowship training in Baltimore and was recruited to the thoracic oncology program to continue work as a physician and clinical scientist focused in lung cancer. Dr. Scott and her team are committed to providing compassionate and individualized care to their patients, including state-of-the-art therapies and clinical trials. Her research interests include clinical trials in resectable lung cancer, innovative applications of immunotherapy, and novel targeted therapies, especially EGFR- and HER2-mutated lung cancers. Dr. Scott is a member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and the International Association for the Study of Lung Cancer (IASLC).
Dr. Scott is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and EGFR Positive Lung Cancer.
Her clinical research consists of co-authoring 73 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Building B, Washington, DC 20016
Additional Areas of Focus
Dr. Scott has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins Bayview Medical Center
Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.
Inova Health Care Services
Janakiraman Subramanian is an Oncologist and a Hematologist in Fairfax, Virginia. Dr. Subramanian is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Subramanian is currently accepting new patients.
Sibley Memorial Hospital
Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an associate professor of oncology for Johns Hopkins University School of Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital. Dr. Levy is a physician scientist who is interested in innovative immunotherapeutic approaches for advanced stage lung cancer patients and biomarkers that help define those patients more likely to respond to such agents. He has an expertise in thoracic malignancies, including non-small cell lung cancer, small cell lung cancer and thymic malignancies, as well as head and neck cancer. Dr. Levy earned his medical degree from Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Center, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his clinical research in prostate cancer. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, medical director of thoracic oncology for Mount Sinai Health Systems and associate director of the Cancer Clinical Trials Office for Mount Sinai Hospital in New York City. Dr. Levy played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as associate editor for the ASCO University Committee. He completed a two year term on the editorial board for the Journal of Clinical Oncology and currently serves as an ad hoc reviewer for other journals, including Clinical Lung Cancer, The Oncologist and Oncotarget. Dr. Levy was recently selected as one of only 15 oncologists in the country to the prestigious ASCO Leadership Development program, whose mission is to identify and develop future leaders of ASCO. In addition to his ASCO commitments, Dr. Levy serves on the ALLIANCE Respiratory Committee, the IASLC Staging Committee and the IASLC Career Development & Fellowship Committee. Dr. Levy is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- ALK-Positive Non-Small Cell Lung Cancer
- EGFR Positive Lung CancerDr. Scott isAdvanced. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Scott isAdvanced. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Scott isAdvanced. Learn about Lung Adenocarcinoma.
- Lung CancerDr. Scott isAdvanced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Experienced
- DehydrationDr. Scott isExperienced. Learn about Dehydration.
- Neuroendocrine TumorDr. Scott isExperienced. Learn about Neuroendocrine Tumor.
- Pleuropulmonary BlastomaDr. Scott isExperienced. Learn about Pleuropulmonary Blastoma.
- Postpartum DepressionDr. Scott isExperienced. Learn about Postpartum Depression.
- RetinoblastomaDr. Scott isExperienced. Learn about Retinoblastoma.
- Thymic Epithelial TumorDr. Scott isExperienced. Learn about Thymic Epithelial Tumor.